A Trial to Evaluate the Absolute Bioavailability of Cenerimod in Healthy Male Participants

The goal of this clinical trial is to learn about the absolute bioavailability of cenerimod in healthy participants. It will also provide information about the safety of cenerimod. Participants will receive one tablet with cenerimod, followed by an intravenous (i.v.) infusion with a 14C-radiolabeled cenerimod microtracer (cenerimod with a very low dose of radioactivity) 6 hours later. Participants will stay at the clinic for a total of 4 days, and will return to the clinic for further tests over the course of approximately 3 months.

NCT Number	NCT07301723
Lead Sponsor	Viatris Innovation GmbH
Conditions	Healthy Subjects
Enrollment	6 participants
Start Date	2025-12-11
Primary Completion	2026-03-18 (estimated)
Study Completion	2026-03-18 (estimated)
Updated on ClinicalTrials.gov	2026-07-14